Dubland Joshua A, Rakić Bojana, Vallance Hilary, Sinclair Graham
Department of Pathology and Laboratory Medicine, British Columbia Children's Hospital, Vancouver, BC, Canada.
British Columbia Children's Hospital Research Institute, Vancouver, BC, Canada.
J Mass Spectrom Adv Clin Lab. 2021 Mar 17;20:1-10. doi: 10.1016/j.jmsacl.2021.03.001. eCollection 2021 Apr.
Inborn errors of propionate, cobalamin and methionine metabolism are targets for Newborn Screening (NBS) in most programs world-wide, and are primarily screened by analyzing for propionyl carnitine (C3) and methionine in dried blood spot (DBS) cards using tandem mass spectrometry (MS/MS). Single-tier NBS approaches using C3 and methionine alone lack specificity, which can lead to an increased false-positive rate if conservative cut-offs are applied to minimize the risk of missing cases. Implementation of liquid chromatography tandem mass spectrometry (LC-MS/MS) second-tier testing for 2-methylcitric acid (MCA), methylmalonic acid (MMA), and homocysteine (HCY) from the same DBS card can improve disease screening performance by reducing the false-positive rate and eliminating the need for repeat specimen collection. However, DBS analysis of MCA, MMA, and HCY by LC-MS/MS is challenging due to limited specimen size and analyte characteristics leading to a combination of low MS/MS sensitivity and poor reverse-phase chromatographic retention. Sufficient MS response and analytical performance can be achieved for MCA by amidation using DAABD-AE and by butylation for MMA and HCY. Herein we describe the validation of a second-tier dual derivatization LC-MS/MS approach to detect elevated MCA, MMA, and HCY in DBS cards for NBS. Clinical utility was demonstrated by retrospective analysis of specimens, an interlaboratory method comparison, and assessment of external proficiency samples. Imprecision was <10.8% CV, with analyte recoveries between 90.2 and 109.4%. Workflows and analytical performance characteristics of this second-tier LC-MS/MS approach are amenable to implementation in the NBS laboratory.
在全球大多数新生儿筛查(NBS)项目中,丙酸、钴胺素和蛋氨酸代谢的先天性缺陷都是筛查对象,主要通过串联质谱(MS/MS)分析干血斑(DBS)卡片中的丙酰肉碱(C3)和蛋氨酸来进行筛查。仅使用C3和蛋氨酸的单层NBS方法缺乏特异性,如果应用保守的临界值以尽量减少漏诊风险,可能会导致假阳性率增加。对同一DBS卡片进行液相色谱串联质谱(LC-MS/MS)二级检测2-甲基柠檬酸(MCA)、甲基丙二酸(MMA)和同型半胱氨酸(HCY),可以通过降低假阳性率和避免重复采集样本,提高疾病筛查性能。然而,由于样本量有限和分析物特性,通过LC-MS/MS对DBS中的MCA、MMA和HCY进行分析具有挑战性,导致MS/MS灵敏度低和反相色谱保留差。通过使用DAABD-AE进行酰胺化以及对MMA和HCY进行丁基化,可以实现MCA足够的质谱响应和分析性能。在此,我们描述了一种二级双衍生化LC-MS/MS方法的验证,用于检测NBS的DBS卡片中升高的MCA、MMA和HCY。通过对标本的回顾性分析、实验室间方法比较以及外部能力验证样本的评估,证明了该方法的临床实用性。不精密度<10.8%CV,分析物回收率在90.2%至109.4%之间。这种二级LC-MS/MS方法的工作流程和分析性能特征适合在NBS实验室实施。